Preinvasive  ||| S:0 E:12 ||| JJ
lesions  ||| S:12 E:20 ||| NNS
in  ||| S:20 E:23 ||| IN
gynaecology -   ||| S:23 E:38 ||| CD
ovary  ||| S:38 E:44 ||| NN
In  ||| S:44 E:47 ||| IN
comparison  ||| S:47 E:58 ||| NN
to  ||| S:58 E:61 ||| TO
malignant  ||| S:61 E:71 ||| JJ
tumors  ||| S:71 E:78 ||| NNS
of  ||| S:78 E:81 ||| IN
vulva ||| S:81 E:86 ||| NN
,  ||| S:86 E:88 ||| ,
vagina ||| S:88 E:94 ||| NN
,  ||| S:94 E:96 ||| ,
cervix  ||| S:96 E:103 ||| NN
and  ||| S:103 E:107 ||| CC
uterine  ||| S:107 E:115 ||| JJ
corpus ||| S:115 E:121 ||| NN
,  ||| S:121 E:123 ||| ,
clear  ||| S:123 E:129 ||| JJ
morphologic  ||| S:129 E:141 ||| NN
and  ||| S:141 E:145 ||| CC
molecular  ||| S:145 E:155 ||| JJ
genetic  ||| S:155 E:163 ||| JJ
features  ||| S:163 E:172 ||| NNS
of  ||| S:172 E:175 ||| IN
precursor  ||| S:175 E:185 ||| JJ
lesions  ||| S:185 E:193 ||| NNS
of  ||| S:193 E:196 ||| IN
ovarian  ||| S:196 E:204 ||| JJ
carcinoma  ||| S:204 E:214 ||| NNS
have  ||| S:214 E:219 ||| VBP
not  ||| S:219 E:223 ||| RB
been  ||| S:223 E:228 ||| VBN
defined  ||| S:228 E:236 ||| VBN
yet ||| S:236 E:239 ||| RB
.  ||| S:239 E:241 ||| .
We  ||| S:241 E:244 ||| PRP
can  ||| S:244 E:248 ||| MD
see  ||| S:248 E:252 ||| VB
an  ||| S:252 E:255 ||| DT
effort  ||| S:255 E:262 ||| NN
to  ||| S:262 E:265 ||| TO
describe  ||| S:265 E:274 ||| VB
preinvasive  ||| S:274 E:286 ||| JJ
lesions  ||| S:286 E:294 ||| NNS
to  ||| S:294 E:297 ||| TO
allow  ||| S:297 E:303 ||| VB
dia-gnostics  ||| S:303 E:316 ||| JJ
and  ||| S:316 E:320 ||| CC
treatment  ||| S:320 E:330 ||| NN
prior  ||| S:330 E:336 ||| RB
to  ||| S:336 E:339 ||| TO
development  ||| S:339 E:351 ||| NN
of  ||| S:351 E:354 ||| IN
invasive  ||| S:354 E:363 ||| JJ
ovarian  ||| S:363 E:371 ||| JJ
cancer ||| S:371 E:377 ||| NN
.  ||| S:377 E:379 ||| .
This  ||| S:379 E:384 ||| DT
tendency  ||| S:384 E:393 ||| NN
is  ||| S:393 E:396 ||| VBZ
magnified  ||| S:396 E:406 ||| VBN
by  ||| S:406 E:409 ||| IN
the  ||| S:409 E:413 ||| DT
fact  ||| S:413 E:418 ||| NN
that  ||| S:418 E:423 ||| IN
ovarian  ||| S:423 E:431 ||| JJ
carcinomas  ||| S:431 E:442 ||| NNS
have  ||| S:442 E:447 ||| VBP
the  ||| S:447 E:451 ||| DT
highest  ||| S:451 E:459 ||| JJS
mortality  ||| S:459 E:469 ||| NN
from  ||| S:469 E:474 ||| IN
all  ||| S:474 E:478 ||| DT
gynecological  ||| S:478 E:492 ||| JJ
malignancies ||| S:492 E:504 ||| NN
.  ||| S:504 E:506 ||| .
Currently ||| S:506 E:515 ||| RB
,  ||| S:515 E:517 ||| ,
reports  ||| S:517 E:525 ||| VBZ
confirming  ||| S:525 E:536 ||| VBG
different  ||| S:536 E:546 ||| JJ
morphology ||| S:546 E:556 ||| NN
,  ||| S:556 E:558 ||| ,
pathogenesis  ||| S:558 E:571 ||| NN
and  ||| S:571 E:575 ||| CC
molecular  ||| S:575 E:585 ||| JJ
alterations  ||| S:585 E:597 ||| NN
in  ||| S:597 E:600 ||| IN
heterogeneous  ||| S:600 E:614 ||| JJ
group  ||| S:614 E:620 ||| NN
of  ||| S:620 E:623 ||| IN
ovarian  ||| S:623 E:631 ||| JJ
carcinomas  ||| S:631 E:642 ||| NNS
have  ||| S:642 E:647 ||| VBP
been  ||| S:647 E:652 ||| VBN
described ||| S:652 E:661 ||| VBN
.  ||| S:661 E:663 ||| .
There  ||| S:663 E:669 ||| EX
is  ||| S:669 E:672 ||| VBZ
a  ||| S:672 E:674 ||| DT
tendency  ||| S:674 E:683 ||| NN
to  ||| S:683 E:686 ||| TO
divide  ||| S:686 E:693 ||| VB
epithelial  ||| S:693 E:704 ||| JJ
malignant  ||| S:704 E:714 ||| JJ
tumors  ||| S:714 E:721 ||| NNS
into  ||| S:721 E:726 ||| IN
two  ||| S:726 E:730 ||| CD
groups ||| S:730 E:736 ||| NNS
.  ||| S:736 E:738 ||| .
Low  ||| S:738 E:742 ||| FW
grade  ||| S:742 E:748 ||| FW
ovarian  ||| S:748 E:756 ||| FW
serous  ||| S:756 E:763 ||| FW
carcinoma ||| S:763 E:772 ||| FW
,  ||| S:772 E:774 ||| ,
low  ||| S:774 E:778 ||| CD
grade  ||| S:778 E:784 ||| NN
endometrioid ||| S:784 E:796 ||| NN
,  ||| S:796 E:798 ||| ,
clear  ||| S:798 E:804 ||| CD
cell ||| S:804 E:808 ||| NN
,  ||| S:808 E:810 ||| ,
mucinous  ||| S:810 E:819 ||| JJ
ovarian  ||| S:819 E:827 ||| JJ
cancers  ||| S:827 E:835 ||| NNS
and  ||| S:835 E:839 ||| CC
Brenner  ||| S:839 E:847 ||| NNP
tumors  ||| S:847 E:854 ||| NNS
of  ||| S:854 E:857 ||| IN
ovary  ||| S:857 E:863 ||| NNS
are  ||| S:863 E:867 ||| VBP
categorized  ||| S:867 E:879 ||| VBN
as  ||| S:879 E:882 ||| IN
type  ||| S:882 E:887 ||| NN
I  ||| S:887 E:889 ||| PRP
ovarian  ||| S:889 E:897 ||| VBP
tumors ||| S:897 E:903 ||| NNS
.  ||| S:903 E:905 ||| .
Highgrade  ||| S:905 E:915 ||| FW
serous  ||| S:915 E:922 ||| FW
carcinoma ||| S:922 E:931 ||| FW
,  ||| S:931 E:933 ||| ,
undifferentiated  ||| S:933 E:950 ||| JJ
carcinomas  ||| S:950 E:961 ||| NN
and  ||| S:961 E:965 ||| CC
malignant  ||| S:965 E:975 ||| JJ
mixed  ||| S:975 E:981 ||| JJ
mesodermal  ||| S:981 E:992 ||| JJ
tumors  ||| S:992 E:999 ||| NNS
of  ||| S:999 E:1002 ||| IN
the  ||| S:1002 E:1006 ||| DT
ovary  ||| S:1006 E:1012 ||| NN
( ||| S:1012 E:1013 ||| -LRB-
MMMTs ||| S:1013 E:1018 ||| NNP
)  ||| S:1018 E:1020 ||| -RRB-
belong  ||| S:1020 E:1027 ||| VBP
to  ||| S:1027 E:1030 ||| TO
type  ||| S:1030 E:1035 ||| NN
II  ||| S:1035 E:1038 ||| NNP
tumors ||| S:1038 E:1044 ||| NNS
.  ||| S:1044 E:1046 ||| .
A  ||| S:1046 E:1048 ||| DT
potential  ||| S:1048 E:1058 ||| JJ
precursor  ||| S:1058 E:1068 ||| JJ
lesion  ||| S:1068 E:1075 ||| NN
of  ||| S:1075 E:1078 ||| IN
highgrade  ||| S:1078 E:1088 ||| JJ
serous  ||| S:1088 E:1095 ||| JJ
ovarian  ||| S:1095 E:1103 ||| JJ
cancer  ||| S:1103 E:1110 ||| NN
has  ||| S:1110 E:1114 ||| VBZ
been  ||| S:1114 E:1119 ||| VBN
defined  ||| S:1119 E:1127 ||| VBN
-   ||| S:1127 E:1130 ||| NNP
serous  ||| S:1130 E:1137 ||| FW
tubal  ||| S:1137 E:1143 ||| FW
intraepithelial  ||| S:1143 E:1159 ||| FW
carcinoma ||| S:1159 E:1168 ||| FW
.  ||| S:1168 E:1170 ||| .
